Список литературы

1. Messenger A.G., McKillop J., Farrant P., McDonagh A.J., Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. British Journal of Dermatology 2012; 166: 916 - 926.

2. Darwin E., Hirt P., Fertig R. et al. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018 Mar - Apr; 10(2): 51 - 60.

3. Strazzulla L.C., Wang E.H.C., Avila L. et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018 Jan; 78 (1): 1 - 12. doi: 10.1016/j.jaad.2017.04.1141

4. Alkhalifah A. Alopecia areata update. Dermatol Clin. 2013; 31: 93 - 108.

5. L., Bergler-Czop B., D., A. New aspects of the treatment of alopecia areata. Postepy Dermatol Alergol. 2014; 31 (4): 262 - 265. doi: 10.5114/pdia.2014.40923

6. Lee S., Lee Y.B., Kim B.J. et al. Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 1410.

7. Lee S., Kim B.J., Lee C.H. et al. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018 Jul; 32 (7): 1214 - 1221.

8. Almohanna H.M., Ahmed A.A., Tsatalis J.P. et al. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019 Mar; 9 (1): 51 - 70. doi: 10.1007/s13555-018-0278-6. Epub 2018 Dec 13.

9. Mahmoudi H., Salehi M., Moghadas S. et al. Dermoscopic findings in 126 patients with alopecia areata: A cross-sectional study. Int J Trichol 2018; 10: 118 - 23.

10. Inui S., Nakajima T., Nakagawa K. et al. Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol. 2008; 47 (7): 688.

11. Jain N., Doshi B., Khopkar U. Trichoscopy in alopecias: diagnosis simplified. Int J Trichology. 2013; 5 (4): 170 - 178. doi: 10.4103/0974-7753.130385

12. Kuty-Pachecka M. Psychological and psychopathological factors in alopecia areata. Psychiatr Pol. 2015; 49 (5): 955 - 64.

13. Dai Y.X., Tai Y.H., Chen C.C. et al. Bidirectional association between alopecia areata and sleep disorders: a population-based cohort study in Taiwan. Sleep Med. 2020 Nov; 75: 112 - 116. doi: 10.1016/j.sleep.2020.06.015. Epub 2020 Jun 14. PMID: 32858349.

14. Терещенко Г.П. Клинико-морфологические особенности и нарушения местных иммунных реакций при гнездной алопеции с учетом стадий активности заболевания//авторефер. на соис. канд. мед. наук., Москва, 2011 - 25 с.

15. Meah N., Wall D., York K. et. al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020 Jul; 83 (1): 123 - 130. doi: 10.1016/j.jaad.2020.03.004. Epub 2020 Mar 9. PMID: 32165196.

16. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55: 632 - 636.

17. Phan K., Ramachandran V., Sebaratnam D.F. Methotrexate for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 Jan; 80 (1): 120 - 127. e2. doi: 10.1016/j.jaad.2018.06.064. Epub 2018 Jul 10.

18. Nowaczyk J., Makowska K., Rakowska A. et al. Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review. Dermatol Ther (Heidelb). 2020 Jun; 10 (3): 387 - 399. doi: 10.1007/s13555-020-00370-2. Epub 2020 Apr 8. PMID: 32270396; PMCID: PMC7211785.

19. Liu L.Y., Craiglow B.G., Dai F., King B.A. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017 Jan; 76 (1): 22 - 28. doi: 10.1016/j.jaad.2016.09.007. Epub 2016 Nov 2. PMID: 27816293.

20. Zheng C., Tosti A. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors. Dermatol Clin. 2021 Jul; 39 (3): 407 - 415. doi: 10.1016/j.det.2021.03.005. Epub 2021 May 15. PMID: 34053594.

21. S., Engin B., U. et al. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients. Dermatol Ther. 2019 May; 32 (3): e12844. doi: 10.1111/dth.12844. Epub 2019 Feb 7. PMID: 30693634.

22. Craiglow B.G., Liu L.Y., King B.A. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol 2017; 76: 29e32.

23. Kubeyinje E.P. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994; 71: 674 - 675.

24. Abell E., Munro D.D. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973; 88: 55 - 59.

25. Shapiro J., Price V.H. Hair regrowth. Therapeutic agents. Dermatol Clin 1998: 16: 341 - 356.

26. Chang K.H, Rojhirunsakool S., Goldberg L.J. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009: 8: 909 - 912.

27. Shapiro J., Madani S. Alopecia areata: Diagnosis and management. Int J Dermatol 1999; 38 (Suppl 1): 19 - 24.

28. Melo D.F., Dutra T.B.S., Baggieri V. et al. Intralesional betamethasone as a therapeutic option for alopecia areata. An Bras Dermatol. 2018 Mar; 93 (2): 311 - 312. doi: 10.1590/abd1806-4841.20187423. PMID: 29723356; PMCID: PMC5916422.

29. Gregoriou S., Kazakos С., Rigopoulos D. Treatment options for alopecia areata, Expert Review of Dermatology 2011, 6: 5, 537 - 548.

30. Zaher H., Gawdat H.I., Hegazy R.A., Hassan M. Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study. Dermatology. 2015; 230 (4): 308 - 13. doi: 10.1159/000371416. Epub 2015 Mar 4. PMID: 25765294.

31. Wang E., Lee J.S., Tang M. Current treatment strategies in pediatric alopecia areata. Indian J Dermatol. 2012 Nov; 57 (6): 459 - 65. doi: 10.4103/0019-5154.103066. PMID: 23248364; PMCID: PMC3519253.

32. Olsen E.A., Carson S.C., Turney E.A. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128 (11): 1467 - 1473.

33. Pascher F., Kurtin S., Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970; 141 (3): 193 - 202.

34. AA., Solak SS., Altunay , NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015; 14 (6): 616 - 620.

35. Maia C., Nurimar F. Therapy of alopecia areata with topical corticosteroid: prospective double-blind controlled assay in children. An. Bras. Dermatol. [online]. 2003, vol. 78, n. 1, pp. 63 - 71. ISSN 1806 - 4841.

36. Tosti A., Piraccini B.M., Pazzaglia M. et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49: 96 - 8.

37. Lenane P., Macarthur C., Parkin P.C. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol. 2014 Jan; 150 (1): 47 - 50. doi: 10.1001/jamadermatol.2013.5764. PMID: 24226568.

38. Ucak H., Kandi B., Cicek D. et al. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatolog Treat. 2012 Dec; 23 (6): 410 - 20. doi: 10.3109/09546634.2011.590788. Epub 2011 Jul 25.

39. Sotiriou E. et al. Tacrolimus ointment 0.1% in the treatment of active patchy alopecia areata of childhood European Journal of Pediatric Dermatology 17(4): 227 - 230.

40. Vila T., Camacho Martinez F. Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata. Int J Trichology. 2010 Jul - Dec; 2 (2): 86 - 88. doi: 10.4103/0974-7753.77511

41. Roseborough I., Lee H., Chwalek J. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009 Apr; 60 (4): 705 - 6. doi: 10.1016/j.jaad.2008.08.029.

42. Mlacker S., Aldahan A.S., Simmons B.J. et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017 Apr; 19 (2): 93 - 99. doi: 10.1080/14764172.2016.1248440. Epub 2017 Jan 25.

43. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol. 2009 Sep - Oct; 26 (5): 547 - 50. doi: 10.1111/j.1525-1470.2009.00980.x.

44. Darwin E., Arora H., Hirt P.A. et al. A review of monochromatic light devices for the treatment of alopecia areata. Lasers Med Sci. 2018 Feb; 33 (2): 435 - 444. doi: 10.1007/s10103-017-2412-6. Epub 2017 Dec 17.

45. Trink A., Sorbellini E., Bezzola P. et al. A randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013; 169: 690 - 4.

46. Sukhbir Singh. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. Indian J Plast Surg. 2015 Jan - Apr; 48 (1): 57 - 59. doi: 10.4103/0970-0358.155271

47. Eckert M.M., Gundin N.L., Crespo R.L. Alopecia areata: good response to treatment with fractional laser in 5 cases. J Cosmo Trichol 2016; 2: 108.

48. Yoo K.H., Kim M.N., Kim B.J., Kim C.W. Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol. 2010 Jul; 49 (7): 845 - 7. doi: 10.1111/j.1365-4632.2009.04230.x. Epub 2009 Jul 13. PMID: 19627384.

49. W. Wang et al. Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. JCD: Aug 2019: volume 18: issue 4; p 1009 - 1013.

50. Barton V.R., Toussi A., Awasthi S., Kiuru M. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022 Jun; 86 (6): 1318 - 1334. doi: 10.1016/j.jaad.2021.04.077. Epub 2021 Apr 30. PMID: 33940103; PMCID: PMC8556406.

51. Craiglow B.G., King B.A. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019 Feb; 80 (2): 568 - 570. doi: 10.1016/j.jaad.2018.08.041. Epub 2018 Sep 6. PMID: 30195571.

52. Royer M.; Bodemer C.; Vabres P.; Pajot C.; Barbarot S.; Paul C.; Mazereeuw J. (2011). Efficacy and tolerability of methotrexate in severe childhood alopecia areata, 165 (2), 407 - 410. doi: 10.1111/j.1365-2133.2011.10383.x

53. Prey S., Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009 Mar; 160 (3): 622 - 8. doi: 10.1111/j.1365-2133.2008.08876.x. Epub 2008 Oct 20. PMID: 18945303.

54. Hammerschmidt M., Mulinari Brenner F. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014 Sep - Oct; 89 (5): 729 - 34. doi: 10.1590/abd1806-4841.20142869. PMID: 25184911; PMCID: PMC4155950.

55. Sharma V.K., Muralidhar S. Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol. 1998; 15: 313 - 7.

56. Sharma V.K., Gupta S. Twice weekly 5mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol. 1999; 26: 562 - 5.

57. Wang E., Lee J.S., Tang M. Current treatment strategies in pediatric alopecia areata. Indian J Dermatol. 2012 Nov; 57 (6): 459 - 65. doi: 10.4103/0019-5154.103066. PMID: 23248364; PMCID: PMC3519253.

58. Borchert M., Bruce S., Wirta D., Yoelin S.G., Lee S., Mao C., VanDenburgh A. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin Ophthalmol. 2016 Mar 10; 10: 419 - 29. doi: 10.2147/OPTH.S89561. PMID: 27022239; PMCID: PMC4792214.

59. Mehta J.S., Raman J., Gupta N., Thoung D. Cutaneous latanoprost in the treatment of alopecia areata. Eye (Lond). 2003; 17 (3): 444 - 446. doi: 10.1038/sj.eye.6700354

60. Bimbi C., Kyriakou G., Wollina U. Occlusive treatment enhances efficacy of tacrolimus 0.1% in a pediatric patient with severe alopecia areata: Case report and literature review. Pediatr Dermatol. 2021; 38 (1): 339 - 340. doi: 10.1111/pde.14474

61. Nassar A., Elradi M., Radwan M., Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study. J Cosmet Dermatol. 2023; 22 (4): 1297 - 1303. doi: 10.1111/jocd.15558

62. Lenane P., Pope E., Krafchik B. Congenital alopecia areata. J Am Acad Dermatol. 2005; 52 (2 Suppl 1): 8 - 11. doi: 10.1016/j.jaad.2004.06.024

63. Lepe K., Syed H.A., Zito P.M. Alopecia Areata. [Updated 2023 Oct 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537000/

64. Bhat S., Handa S., De D. A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata. Indian J Dermatol Venereol Leprol. 2021; 87 (1): 42 - 48. doi: 10.25259/IJDVL_787_19

65. Fiedler-Weiss V.C. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987; 16 (3 Pt 2): 745 - 748. doi: 10.1016/s0190-9622(87)80003-8

66. Piraccini B.M. A new era for alopecia areata: New treatments and improved knowledge of the condition. J Eur Acad Dermatol Venereol. 2024; 38: 458 - 459. https://doi.org/10.1111/jdv.19741

67. Senna M., Mostaghimi A., Ohyama M. et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024; 38 (3): 583 - 593. doi: 10.1111/jdv.19665

68. Freire P.C.B., Riera R., Martimbianco A.L.C., Petri V., Atallah A.N. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 Sep; 33 (9): 1792 - 1799. doi: 10.1111/jdv.15545. Epub 2019 Jun 28. PMID: 30835901.

69. Olsen E.A., Carson S.C., Turney E.A. Systemic Steroids With or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata. Arch Dermatol. 1992; 128 (11): 1467 - 1473. doi: 10.1001/archderm.1992.01680210045005

70. I.M., E.M., F.M. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010 Apr; 24 (4): 481 - 5. doi: 10.1111/j.1468-3083.2009.03543.x. Epub 2009 Dec 17. PMID: 20028444

71. El Taieb M.A., Ibrahim H., Nada E.A., Seif Al-Din M. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. Dermatol Ther. 2017 Jan; 30 (1). doi: 10.1111/dth.12437. Epub 2016 Oct 28. PMID: 27791311.

72. Albalat W., Ebrahim H.M. Evaluation of platelet-rich plasma vs intralesional steroid in treatment of alopecia areata. J Cosmet Dermatol. 2019 Oct; 18 (5): 1456 - 1462. doi: 10.1111/jocd.12858. Epub 2019 May 10. PMID: 31074201

73. King B., Ohyama M., Kwon O., Zlotogorski A., Ko J., Mesinkovska N.A., Hordinsky M., Dutronc Y., Wu W.S., McCollam J., Chiasserini C., Yu G., Stanley S., Holzwarth K., DeLozier A.M., Sinclair R.; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5; 386 (18): 1687 - 1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.

74. Alam M, Amin SS, Adil M, Arif T, Zahra FT, Varshney I. Comparative Study of Efficacy of Topical Mometasone with Calcipotriol versus Mometasone Alone in the Treatment of Alopecia Areata. Int J Trichology. 2019 May - Jun; 11(3): 123 - 127. doi: 10.4103/ijt.ijt_18_19. PMID: 31360041; PMCID: PMC6580810.

75. Lassus A., Eskelinen A., Johansson E. Treatment of alopecia areata with three different PUVA modalities. Photodermatology 1984; 1: 141 - 144.

76. Van der Schaar W.W., Sillevis Smith J.H. An evaluation of PUVA-therapy for alopecia areata. Dermatologica 1984; 168: 250 - 252.

77. Mitchell A.J., Douglass M.C. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12: 644 - 649.

78. Taylor C.R., Hawk J.L. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133: 914 - 918.

79. Shishak M., Mahajan B. Alternate treatment of alopecia areata with the use of calcipotriol: A prospective study in children versus adults. Journal of the American Academy of Dermatology. volume 79, issue 3, supplement 1, ab35, 2018. doi.org/10.1016/j.jaad.2018.05.179

80. Freire P.C.B., Riera R., Martimbianco A.L.C., Petri V., Atallah A.N. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 Mar 5. doi: 10.1111/jdv.15545.

81. Mohamed Z., Bhouri A., Jallouli A., et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol. 2005; 19: 552 - 555.

82. Kamel M.M., Salem S.A., Attia H.H. Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8-methoxypsoralen application. Photodermatol Photoimmunol Photomed. 2011; 27: 45 - 50.

83. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5; 386(18): 1687 - 1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.

84. El-Ashmawy, Amal Ahmad; El-Maadawy, Iman Hamed; El-Maghraby, Gamal Mohamed (2017). Efficacy of Topical Latanoprost Versus Minoxidil and Betamethasone Valerate on The Treatment of Alopecia Areata. Journal of Dermatological Treatment, 1 - 31. doi: 10.1080/09546634.2017.1330527

85. Siva Kumar Sivasubramaniam, Kode Leela Sravanthi. A comparative study of efficacy of minoxidil 2% and hair serum in alopecia areata in a tertiary care center at Karaikal, Puducherry. International Journal of Current Advanced Research. Volume 9; Issue 12 (A); December 2020. DOI: http://dx.doi.org/10.24327/ijcar.2020

86. Messenger A.G., Hordinsky M. Alopecia areata: management//UpToDate. Riverwoods, IL: Wolters Kluwer. - 2021. https://medilib.ir/uptodate/show/3319

87. Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May; 24(3): 443 - 451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. PMID: 36855020; PMCID: PMC9974384.